secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K/A
Filed at:   2023-01-17T23:59:59+00:00
Accession:  0001193125-23-009540
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma files merger financials: 2021 revenue $5.5M, net loss $20.2M
-----------------------------------------------------------------------

- Audited 2021 revenue $5.5M vs $17.8M in 2020; net loss $20.2M vs $1.1M.
- Cash $60.1M at Dec 31, 2021; accumulated deficit $42.3M; expects continued losses.
- Product candidate ARS-1 (Neffy) for needle-free epinephrine in anaphylaxis.
- Merger with Silverback closed Nov 2022; this amendment provides previously missing financials.
- Pro forma combined financials filed as Exhibit 99.3; shows combined entity post-merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523009540/0001193125-23-009540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312523009540/d448105d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-009540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer